Stati Uniti - Ingliż - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. although rare, sensitivity to sodium sulfacetamide may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. if the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. particular caution should be employed if areas of denuded or abraded skin are involved. systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed. information for patients: patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. the use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. avoid contact with eyes, lips and mucous membranes. drug interactions: this product is incompatible with silver preparations. carcinogenesis, mutagenesis and impairment of fertility: long-term animal studies for carcinogenic potential have not been performed on this product to date. studies on reproduction and fertility also have not been performed. chromosomal nondisjunction has been reported in the yeast, saccharomyces cerevisiae, following application of sodium sulfacetamide. the significance of this finding to the topical use of sodium sulfacetamide in the human is unknown. pregnancy: category c. animal reproduction studies have not been conducted with this product. it is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. this product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus. nursing mothers: it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman. pediatric use: safety and effectiveness in children under the age of 12 years have not been established.

Kanada - Ingliż - Health Canada

pharma stulln inc. - sulfacetamide sodium; prednisolone acetate - suspension - 10%; 0.5% - sulfacetamide sodium 10%; prednisolone acetate 0.5% - sulfonamides

Stati Uniti - Ingliż - NLM (National Library of Medicine)

acella pharmaceuticals, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - indications: sodium sulfacetamide 10% sulfur 5% emollient cream is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. contraindications: sodium sulfacetamide 10% sulfur 5% emollient cream is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation.sodium sulfacetamide 10% sulfur 5% emollient cream is not to be used by patients with kidney disease. pediatric use: safety and effectiveness in children under the age of 12 have not been established.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

canton laboratories - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sodium sulfacetamide 10% wash is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. sodium sulfacetamide 10% wash is contraindicated in persons with known or suspected hypersensitivity to sulfonamides or to any of the ingredients of the product. safety and effectiveness in children under the age of 12 years have not been established.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

bryant ranch prepack - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sodium sulfacetamide 10% - sulfur 2% cleanser is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sodium sulfacetamide 10% - sulfur 2% cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sodium sulfacetamide 10% - sulfur 2% cleanser is not to be used by patients with kidney disease.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

seton pharmaceuticals - sulfacetamide (unii: 4965g3j0f5) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide 100 mg in 1 ml - 10% sodium sulfacetamide 5% sulfur cleanser (in a urea vehicle) is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. 10% sodium sulfacetamide 5% sulfur cleanser (in a urea vehicle) is contraindicated for patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. 10% sodium sulfacetamide 5% sulfur cleanser (in a urea vehicle) is not to be used by patients with kidney disease.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

prugen, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 80 mg in 1 ml - sulfacleanse® 8/4 (sodium sulfacetamide 8% & sulfur 4%) is indicated for the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sulfacleanse® 8/4 (sodium sulfacetamide 8% & sulfur 4%) is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sulfacleanse® 8/4 (sodium sulfacetamide 8% & sulfur 4%) is not to be used by patients with kidney disease.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

remedyrepack inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml

Stati Uniti - Ingliż - NLM (National Library of Medicine)

asclemed usa, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - indications and usage: sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. contraindications: sulfacetamide sodium ophthalmic solution is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

akron pharma inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sodium sulfacetamide 9% - sulfur 4% topical suspension is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sodium sulfacetamide 9% - sulfur 4% topical suspension is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sodium sulfacetamide 9% - sulfur 4% topical suspension is not to be used by patients with kidney disease.